Roche reports data from Phase III retinal vein occlusion therapy trials

Roche reports data from Phase III retinal vein occlusion therapy trials

Source: 
Clinical Trials Arena
snippet: 

Roche reported the latest 72-week data from two Phase III trials, BALATON and COMINO, in which its bispecific antibody Vabysmo (faricimab) demonstrated to be effective in treating macular oedema due to branch and central retinal vein occlusion (BRVO and CRVO).